Registration Now Open for Tribe Public’s Webinar Event "The Important Role For Inhalation Therapy In Oncology" Featuring The Management Team From Atossa Therapeutics on August 25, 2022
22 août 2022 09h30 HE
|
Atossa Therapeutics, Inc.
SAN FRANCISCO, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in areas of significant...
Atossa Therapeutics Appoints Dr. Paul Wabnitz to Its Scientific Advisory Board
18 août 2022 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate Update
08 août 2022 16h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, Aug. 08, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and...
Dosing Completed in Part C of Atossa’s Phase 1/2a Study of AT-H201 in Healthy Volunteers
28 juil. 2022 09h00 HE
|
Atossa Therapeutics, Inc.
SEATTLE, July 28, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa Therapeutics Appoints Biotech Industry Communications Veteran Charles Butler as Vice President, Investor Relations and Public Relations
02 juin 2022 16h05 HE
|
Atossa Therapeutics, Inc.
SEATTLE, June 02, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of...
Atossa Therapeutics to Present at the H.C. Wainwright Global Hybrid Investment Conference
18 mai 2022 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, May 18, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative proprietary medicines in areas of...
Atossa Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate Update
09 mai 2022 16h05 HE
|
Atossa Therapeutics, Inc.
SEATTLE, May 09, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative proprietary medicines in oncology and...
Atossa Therapeutics to Present at the Q2 Investor Summit Conference
27 avr. 2022 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, April 27, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company seeking to develop innovative medicines in areas of significant unmet...
Atossa Therapeutics Announces Completion of Part B of Clinical Study of AT-H201
20 avr. 2022 09h30 HE
|
Atossa Therapeutics, Inc.
NEBULIZED FORMULATION BEING DEVELOPED TO IMPROVE LUNG FUNCTION IN BOTH ACTIVE-DISEASE COVID-19 PATIENTS AND “LONG HAUL” PATIENTS WITH POST-INFECTION PULMONARY DISEASE SEATTLE, April 20, 2022 (GLOBE...
Atossa Therapeutics to Present at the Maxim Group 2022 Virtual Growth Conference
23 mars 2022 09h30 HE
|
Atossa Therapeutics, Inc.
SEATTLE, March 23, 2022 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company seeking to develop innovative medicines in oncology and infectious...